← Back to Search

Quadratus Lumborum vs Erector Spinae Blocks for Postoperative Hip Surgery Pain

Phase 4
Waitlist Available
Led By ROLAND BRUSSEAU, MD
Research Sponsored by Boston Children's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ASA I - III status, undergoing unilateral periacetabular osteotomy for treating primary diagnosis of developmental acetabular dysplasia in symptomatic young patients.
Ages 15 - 30 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 12 hours
Awards & highlights

Study Summary

This trial will compare the efficacy of two types of blocks - Quadratus Lumborum (QL) and Erector Spinae (ESP) - used in conjunction with a continuous lumbar plexus block (LPB) for postoperative analgesia in children and adolescents undergoing unilateral hip surgical procedures.

Who is the study for?
This trial is for young individuals aged 15-30 with developmental acetabular dysplasia experiencing hip pain, who are undergoing unilateral hip surgery. They must be in good health (ASA I - III status) and not overweight (BMI ≤ 35). Those with blood clotting issues, severe neurodevelopmental delays, chronic pain syndromes, recent opioid use, or without parental/patient consent are excluded.Check my eligibility
What is being tested?
The study tests the effectiveness of two types of nerve blocks—quadratus lumborum block (QLB) and erector spinae block (ESB)—when used alongside a continuous lumbar plexus block for post-surgery pain relief in hip PAO surgery. It aims to determine if there's a difference in pain control between these two methods.See study design
What are the potential side effects?
Ropivacaine used in both QLB and ESB may cause side effects like low blood pressure, nausea, vomiting, backache or soreness at the injection site. Serious side effects are rare but can include seizures or heart problems.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am having surgery for hip dysplasia and my health is relatively good.
Select...
I am between 15 and 30 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pacu stay
This trial's timeline: 3 weeks for screening, Varies for treatment, and pacu stay for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rescue analgesic consumption
Secondary outcome measures
Adverse events
Mean pain scores
PACU Time

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Erector spinae supplemental blockExperimental Treatment2 Interventions
Single-shot T9/T10 operative side erector spinae block using ropivacaine 0.2%, 0.5ml/kg.
Group II: Quadratus lumborum supplemental blockActive Control2 Interventions
Single-shot T9/T10 operative side quadratus lumborum (type 1) block using ropivacaine 0.2%, 0.5ml/kg.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ropivacaine
FDA approved

Find a Location

Who is running the clinical trial?

Boston Children's HospitalLead Sponsor
756 Previous Clinical Trials
5,579,008 Total Patients Enrolled
3 Trials studying Postoperative Pain
145 Patients Enrolled for Postoperative Pain
ROLAND BRUSSEAU, MDPrincipal InvestigatorBoston Children's Hospital
3 Previous Clinical Trials
155 Total Patients Enrolled
1 Trials studying Postoperative Pain
45 Patients Enrolled for Postoperative Pain

Media Library

Ropivacaine Clinical Trial Eligibility Overview. Trial Name: NCT04481451 — Phase 4
Postoperative Pain Research Study Groups: Erector spinae supplemental block, Quadratus lumborum supplemental block
Postoperative Pain Clinical Trial 2023: Ropivacaine Highlights & Side Effects. Trial Name: NCT04481451 — Phase 4
Ropivacaine 2023 Treatment Timeline for Medical Study. Trial Name: NCT04481451 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you discuss the security profile of Ropivacaine?

"Reacting to the extensive clinical data, our team at Power assigned Ropivacaine a rating of 3 on safety scale. This is due to its Phase 4 status, which indicates FDA approval."

Answered by AI

How many individuals have enrolled in this research project thus far?

"Affirmative. Evidence on clinicaltrials.gov clarifies that this experiment is currently searching for participants, which was first published on December 1st 2020 and has most recently been updated on September 8th 2022. A total of 156 patients are required from lone medical centre."

Answered by AI

What medical treatments is Ropivacaine typically utilized for?

"Ropivacaine is a common anesthetic used to relieve pain in surgical procedures, childbirth and postoperative care."

Answered by AI

Are there still opportunities for enrolment in this experiment?

"According to clinicaltrials.gov, the enrolment process for this medical trial is ongoing; it was initiated on December 1st 2020 and edited lastly on September 8th 2022."

Answered by AI

Is there an age restriction for participants of this medical experiment?

"Those wishing to enter this trial must be aged 15-30. Simultaneously, there are 93 clinical trials for those under 18 and 439 studies targeting people over 65 years of age."

Answered by AI

For whom is this research endeavor open?

"Participants must be between 15 and 30 years of age, present with postoperative pain, to qualify for this 156-person clinical trial."

Answered by AI
~29 spots leftby Dec 2024